British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, ...

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

GSK PLC GSK shares rose 2.17% to £14.35 Wednesday, on what proved to be an all-around positive trading session for the stock ...

Topline Pharmaceutical heavyweight GSK on Wednesday said it had settled four lawsuits in the U.S. that claimed its popular heartburn drug Zantac causes cancer, averting a trial due to start in ...

GSK does have some important weaknesses as an investment vehicle, however. Chief among them is the lack of a clear-cut all-star in areas like cancer, rare diseases, or metabolic disorders.

GSK PLC GSK shares slid 1.72% to £13.73 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.24% to 9,164.31. GSK PLC ...